All In Biotech

Drug Trial Radar · NCT06012565

KAND567 Versus Placebo in Subjects Hospitalized With COVID-19

KAND567 Versus Placebo in Subjects Hospitalized With COVID-19. A Phase II, Randomized, 2-Arm Parallel-Group, Double-blind Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics

Last checked: Nov 19, 2026Latest source record: Aug 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

35

Actual

Start

Oct 11, 2020

Primary completion

Aug 7, 2021

Study completion Aug 7, 2021

Sponsor

Lead sponsor
Novakand Pharma ABIndustry
Sponsor type
Industry
First posted
Aug 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a phase II, randomized, 2-arm parallel-group, double-blind study to explore the efficacy, safety, tolerability and pharmacokinetics of KAND567 versus placebo in COVID-19 subjects in need of oxygen treatment. The target was to include forty (40) subjects with diagnosed COVID-19 for participation in the study. If at screening all criteria for study participation were fulfilled and informed consent signed, the subject was enrolled and randomized into one of the two arms. After randomization, the subjects were to receive KAND567 or placebo treatment for 7 days. After the treatment period the subjects returned to ordinary clinical follow-up, but a study follow-up visit was to be planned for Day 21 and 90.

Conditions

  • Covid19

Interventions

  • KAND567Drug

    2 x 125 mg capsules for oral administration. KAND567 (250 mg) was to be given every 12 hours for one week (7 days).

  • Microcrystalline celluloseDrug

    Capsules for oral administration, consisting of microcrystalline cellulose oral solid formulation in capsules. Placebo was to be given every 12 hours for one week (7 days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of KAND567, as measured by the occurrence of adverse events (AEs) and serious adverse events (SAEs).Time frame: From the first IMP administration (Day 1) until the last follow-up visit (Day 90).

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Hvidovre Hospital

    Hvidovre, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Capio St. Görans Hospital

    Stockholm, Sweden

  • Västmanlands Hospital

    Västerås, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.